Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia
Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness, and is on track to report topline data by year-end 2026. Placebo-controlled Phase 2 trial is assessing RJx-01’s safety profile and its effects on muscle strength, physical function and muscle fatigue resistance. Productive discussions with regulatory authorities to define the development pathway for RJx-01 in sarcopenia are ongoing.
LEARN MORE